Zeljka Jutric1, W Cory Johnston1, Helena M Hoen1, Pippa H Newell1, Maria A Cassera1, Chet W Hammill2, Ronald F Wolf2, Paul D Hansen3. 1. Hepatobiliary and Pancreatic Surgery Program, Providence Cancer Center, Portland, OR, USA. 2. Hepatobiliary and Pancreatic Surgery Program, Providence Cancer Center, Portland, OR, USA; Providence Cancer Center, Portland, OR, USA; Gastrointestinal and Minimally Invasive Surgery Division, The Oregon Clinic, Portland, OR, USA. 3. Hepatobiliary and Pancreatic Surgery Program, Providence Cancer Center, Portland, OR, USA; Providence Cancer Center, Portland, OR, USA; Gastrointestinal and Minimally Invasive Surgery Division, The Oregon Clinic, Portland, OR, USA. Electronic address: phansen@orclinic.com.
Abstract
INTRODUCTION: Routine lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) is not routinely performed. We aim to define predictive indicators of survival in patients with positive lymph nodes. METHODS: The National Cancer Data Base (NCDB) was queried for patients who underwent major hepatectomy for ICC between 1998 and 2011. Clinical and pathologic data were assessed using uni- and multi-variate analyses. A sub-analysis was performed on the 160 patients with positive lymph nodes. RESULTS: Of 849 patients with lymph node data, 57% had at least one lymph node examined. Median survival for lymph node negative patients was 37 months versus 15 months for lymph node positive patients. In lymph node positive patients, poorer survival was associated with not receiving chemotherapy (HR 1.83, p = 0.003), tumor size > 5 cm (p = 0.029), and older age (p < 0.0001). Lymph node positive patients age less than 45 had a median survival of 27 months. CONCLUSIONS: Overall survival in patients with lymph node metastases from ICC is poor. Adjuvant therapy was associated with a longer survival in lymph node positive patients, although prospective data are needed. Routine lymphadenectomy should be strongly considered to provide prognostic information and guidance for adjuvant therapy.
INTRODUCTION: Routine lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) is not routinely performed. We aim to define predictive indicators of survival in patients with positive lymph nodes. METHODS: The National Cancer Data Base (NCDB) was queried for patients who underwent major hepatectomy for ICC between 1998 and 2011. Clinical and pathologic data were assessed using uni- and multi-variate analyses. A sub-analysis was performed on the 160 patients with positive lymph nodes. RESULTS: Of 849 patients with lymph node data, 57% had at least one lymph node examined. Median survival for lymph node negative patients was 37 months versus 15 months for lymph node positive patients. In lymph node positive patients, poorer survival was associated with not receiving chemotherapy (HR 1.83, p = 0.003), tumor size > 5 cm (p = 0.029), and older age (p < 0.0001). Lymph node positive patients age less than 45 had a median survival of 27 months. CONCLUSIONS: Overall survival in patients with lymph node metastases from ICC is poor. Adjuvant therapy was associated with a longer survival in lymph node positive patients, although prospective data are needed. Routine lymphadenectomy should be strongly considered to provide prognostic information and guidance for adjuvant therapy.
Authors: Giorgio Ercolani; Gian Luca Grazi; Matteo Ravaioli; Walter Franco Grigioni; Matteo Cescon; Andrea Gardini; Massimo Del Gaudio; Antonino Cavallari Journal: Ann Surg Date: 2004-02 Impact factor: 12.969
Authors: Sean P Martin; Justin Drake; Michael M Wach; Samantha Ruff; Laurence P Diggs; Jim Y Wan; Zachary J Brown; Reed I Ayabe; Evan S Glazer; Paxton V Dickson; Jeremy L Davis; Jeremiah L Deneve; Jonathan M Hernandez Journal: Ann Surg Oncol Date: 2019-03-20 Impact factor: 5.344
Authors: Ariella M Altman; Scott Kizy; Schelomo Marmor; Jane Y C Hui; Todd M Tuttle; Eric H Jensen; Jason W Denbo Journal: Hepatobiliary Surg Nutr Date: 2020-10 Impact factor: 7.293
Authors: David G Brauer; Ryan C Fields; Benjamin R Tan; M B Majella Doyle; Chet W Hammill; William G Hawkins; Graham A Colditz; William C Chapman Journal: HPB (Oxford) Date: 2018-01-20 Impact factor: 3.647
Authors: Joshua S Jolissaint; Kevin C Soares; Kenneth P Seier; Ritika Kundra; Mithat Gönen; Paul J Shin; Thomas Boerner; Carlie Sigel; Ramyasree Madupuri; Efsevia Vakiani; Andrea Cercek; James J Harding; Nancy E Kemeny; Louise C Connell; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; T Peter Kingham; Alice C Wei; William R Jarnagin Journal: Clin Cancer Res Date: 2021-05-07 Impact factor: 12.531
Authors: T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica Journal: Curr Probl Surg Date: 2020-06-30 Impact factor: 1.909